The DOI matches its Crossref record.
Antidepressants and Body Weight: A Comprehensive Review and Meta-Analysis
Abstract
OBJECTIVE: Psychotropic drugs often induce weight gain, leading to discomfort and discontinuation of treatment and, more importantly, increasing the risk of obesity-related illnesses such as diabetes mellitus, hypertension, and coronary heart disease. There is evidence that antidepressant drugs may induce a variable amount of weight gain, but results are sparse and often contradictory. DATA SOURCES: We performed a literature search using the MEDLINE, ISI Web of Knowledge, and Cochrane research databases for all publications available to January 2009. We used the following keywords: antidepressant, psychotropic drugs, body weight, weight gain, obesity, overweight, adverse event, side effects, SSRIs, tricyclic antidepressants, and the name of each antidepressant active compound together with body weight or other keywords. Studies reporting body weight changes during treatment with different antidepressants were selected for eligibility. Finally, 116 studies were included in the analysis. DATA EXTRACTION: Weight change mean and standard deviation and size of each group were recorded. Missing means and standard deviations were directly calculated by using information available in the article when possible. Non-placebo-controlled studies were compared to a virtual placebo sample, whose mean and standard deviation were derived by the weighted mean of means and standard deviations of all placebo samples. Methodological quality of studies, heterogeneity, publication bias, and effect of treatment duration were systematically controlled. DATA SYNTHESIS: Quantitative results evidenced that amitriptyline, mirtazapine, and paroxetine were associated with a greater risk of weight gain. In contrast, some weight loss occurs with fluoxetine and bupropion, although the effect of fluoxetine appears to be limited to the acute phase of treatment. Other compounds have no transient or negligible effect on body weight in the short term. However, the effect of each antidepressant may vary greatly depending on an individual's characteristics and generally became more evident in the long term to a variable degree across compounds. CONCLUSIONS: Despite the fact that some analyses were done on only a few studies due to the difficulty of finding reliable information in literature, to our knowledge, this is the first comprehensive meta-analysis to allow comparison of different antidepressants as regards their impact on body weight. Data presented may be helpful for a more accurate treatment selection in patients at risk of obesity or related medical illness.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the persistence of some residual symptoms (e.g., cognitive and sleep disturbances)”
From The revival of psilocybin between scientific excitement, evidence of efficacy, and real-world challenges (2024) · cites this paper as [5]
In the citing paper
“The sedative antidepressants may also induce a weight gain, what is particularly shown for mirtazapine but not for trazodone [23].”
From Effects of Antidepressants on Sleep (2017) · cites this paper as [23]
In the citing paper
“Amitriptyline and mirtazapine consistently showed weight gaining effects throughout acute and long-term treatment.”
From Addressing the Side Effects of Contemporary Antidepressant Drugs: A Comprehensive Review (2018) · cites this paper as [70]
In the citing paper
“A meta-analysis further showed that SSRIs including citalopram, escitalopram, fluoxetine, sertraline, paroxetine and SNRIs including venlafaxine and duloxetine were associated with weight loss compared with placebo.”
From Addressing the Side Effects of Contemporary Antidepressant Drugs: A Comprehensive Review (2018) · cites this paper as [70]
In the citing paper
“Imipramine and bupropion showed significant weight loss effects for both acute and long term treatment (Table 5).70”
From Addressing the Side Effects of Contemporary Antidepressant Drugs: A Comprehensive Review (2018) · cites this paper as [70]
Citations
Cited by
Sorted by citations
Items 401–500 of 622
Psychiatric Disorders and Diabetes
Holt, R. I. G., & Citrome, L. (2016) · Wiley eBooks · doi:10.1002/9781118924853.ch57 · Cited by 4
Tong, G., Zhang, C., Li, H., Gao, X., Velu, P., Safargar, M., Prabahar, K., Xie, H., & Wang, X. (2025) · BMC Psychiatry · doi:10.1186/s12888-025-07441-8 · Cited by 3
“Previous studies have reported weight loss in patients receiving SSRIs for acute conditions [48], and one meta-analysis found that adults taking fluoxetine lost an average of 1.3 kg [49].”
InfluentialDrawbacks of Olanzapine Therapy: An Emphasis on Its Metabolic Effects and Discontinuation
Oruch, R., Rajab, H. A., Elderbi, M., Pryme, I. F., Fasmer, O. B., & Lund, A. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14228125 · Cited by 3
“…include selective serotonin reuptake inhibitors (SSRIs) and serotonin–norepinephrine reuptake inhibitors (SNRIs), and the agents of these two antidepressant groups indeed cause a slight weight loss to start with but with prolonged therapy, many agents of these two groups cause weight gain [79,80].”
InfluentialDell’Osso, B. M., Blasi, G., Serafini, G., Serrati, C., Bianchetti, A., Porto, I., Forleo, G. B., Pugliese, A., Mastrostefano, A., & Nicoletti, F. (2025) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2025.2602193 · Cited by 2
“…anticholinergic activity, such as tricyclic antidepressants (TCAs) or paroxetine, and those with high affinity for histamine H1 receptors – including citalopram, trazodone, mirtazapine, and TCAs – are particularly associated with greater weight gain in both short-and long-term studies [71].”
InfluentialGranata, N., Vercesi, M., Bonfanti, A., Mencacci, C., Coco, I., Mangrella, M., Piazza, R., & Cerveri, G. (2025) · Geriatrics · doi:10.3390/geriatrics10020032 · Cited by 4
“In older adults, there is growing evidence that antidepressant use is associated with significant side effects, including weight gain [95], cognitive impairment [27,96,97], falls [25,98–100], syndrome of inappropriate antidiuretic hormone secretion [101], and serotonin syndrome [102].”
The Controversy Over Antidepressant Drugs in an Era of Evidence-Based Practice
Littrell, J. L., & Lacasse, J. R. (2012) · Social Work in Mental Health · doi:10.1080/15332985.2012.699444 · Cited by 3
Moinfar, Z., Sedaghat, M., Abolhassani, F., Sharifi, V., Moinfar, Z., Eftekhari, S., & Mirzaaghaee, F. (2016) · Journal of Public Health · doi:10.1007/s10389-016-0722-y · Cited by 4
El‐Khoury, J., Beayno, A., Elbejjani, M., Ahad, M. A. A., Majari, G., Ahmad, A., & Noufi, P. E. (2020) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000309 · Cited by 3
“…our study was that fluoxetine did not differ from other antidepressants in its effect on weight even though it is generally accepted in the literature that it is associated with weight loss in the early phases of treatment (Serretti and Mandelli, 2010; Blumenthal et al., 2014; Salvi et al., 2016).”
BackgroundResultInfluentialCongenital anomalies and spontaneous abortion in mice resulting from the use of escitalopram
Sestário, C. S., Mestre, V. D. F., Martins, C. C. N., Zeffa, A. C., Frítola, M., & Salles, M. J. S. (2022) · Reproduction Fertility and Development · doi:10.1071/rd22033 · Cited by 3
Psychoactive drugs and metabolic disorders
Bezerra, T. P. T., Fabrício, A. I. C. R., Minervino, A. J., et al. (2023) · Debates em Psiquiatria · doi:10.25118/2763-9037.2023.v13.439 · Cited by 3
Greene, C., Blackbourn, L. A. K., McGurnaghan, S. J., Mercer, S. W., Smıth, D. J., Wild, S. H., Wu, H., & Jackson, C. (2024) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.16171 · Cited by 3
Bannert, U., Siewert‐Markus, U., Klinger-König, J., Grabe, H. J., Stracke, S., Dörr, M., Völzke, H., Markus, M. R. P., Töpfer, P., & Ittermann, T. (2024) · European Psychiatry · doi:10.1192/j.eurpsy.2024.1764 · Cited by 5
“Across obesity-related traits, effects related to current antidepressant intake were more consistent and larger in women compared to men (Supplementary Table S3).”
Antidepressant induced weight gain associated with anti-histaminergic activity
Salvi, V., Mencacci, C., & Barone‐Adesi, F. (2018) · BMJ · doi:10.1136/bmj.k3222 · Cited by 3
Influencia de la administración de psicofármacos en el aumento del peso corporal
de Morentin, B. E. M., de Eguilaz, M. H. R., Pérez-Díez, S., & Martínez-Hernández, J. A. (2013) · Revista Española de Nutrición Humana y Dietética · doi:10.14306/renhyd.17.1.4 · Cited by 3
Managing Comorbid Illness in Obstructive Sleep Apnea
Conwell, W. D., & Tsai, S. C. (2016) · Sleep Medicine Clinics · doi:10.1016/j.jsmc.2016.04.007 · Cited by 3
Hampton-Anderson, J. N., Trotman, H. D., Addington, J., Bearden, C. E., Cadenhead, K. S., Cannon, T. D., Cornblatt, B. A., Mathalon, D. H., McGlashan, T. H., Tsuang, M. T., et al. (2018) · Stress and Health · doi:10.1002/smi.2819 · Cited by 4
“…at CHR for psychosis are often prescribed AD and AT medications (Walker et al., 2009) and AD medications have also been linked to weight changes (Serretti & Mandelli, 2010), all analyses were performed for both ATs and ADs, the majority of which were selective serotonin reuptake inhibitors…”
Clinical Characterisation of the Co-Occurrence of Mental and Physical Disorders
Holt, R. I. G. (2025) · Springer eBooks · doi:10.1007/978-3-031-81802-8_6 · Cited by 2
Seifert, J., Bleich, S., & Seifert, R. (2025) · Springer eBooks · doi:10.1007/978-3-662-70594-0_22 · Cited by 2
Comparative BMI-z Changes With Initiation and Adherence to Antidepressant Medications Among Youth
Rifas‐Shiman, S. L., Young, J. G., Yu, H., et al. (2025) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2025.11.008 · Cited by 2
Chan, A. C. Y. (2025) · Cureus · doi:10.7759/cureus.98677 · Cited by 4
Spina, E., Barbieri, M. A., Alborghetti, M., Nicoletti, F., & de León, J. (2026) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2026.2650188 · Cited by 3
Zhang, Z., Huang, S. H. M., Li, Z., Cai, X., Qiu, X., Zhang, Z., & Huang, Y. (2026) · Journal of Integrative Neuroscience · doi:10.31083/jin44692 · Cited by 2
Lafer, B., Neves, L. M., Vancampfort, D., Stubbs, B., Gonzalez-Pinto, A., Nierenberg, A. A., Olagunju, A. T., Goldstein, B. I., Vieta, E., Koning, E., et al. (2026) · Bipolar Disorders · doi:10.1111/bdi.70164 · Cited by 2
“Weight gain, which is related to most diseases mentioned, often occurs with medications such as antidepressants and antipsychotics [109, 120, 128].”
Challenges in the management of depressive disorders comorbid with tuberculosis and type 2 diabetes
Caceres-Cardenas, G., Ruíz-Grosso, P., & Ugarte‐Gil, C. (2023) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000885 · Cited by 2
Long-term changes in adiposity markers during and after antidepressant therapy in a community cohort
Mwinyi, J., Strippoli, M. F., Kanders, S. H., Schiöth, H. B., Eap, C. B., Lasserre, A. M., Marques-Vidal, P. M., Vandeleur, C. L., & Preisig, M. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-03032-5 · Cited by 3
“…paroxetine were associated with greater risk of weight gain, whereas the SSRI fl uoxetine and the norepinephrine and dopamine reuptake inhibitor (NDRI) bupropion were associated with weight loss, although this effect of fl uoxetine was limited to the 4 – 12 week ’ s acute treatment phase [10].”
BackgroundMethodResultInfluentialInverse association between obesity and suicidal death risk
Lee, J., Lee, S., Kim, M., Kwon, H., Yun, J., Yang, Y., Yoon, K., Cho, J., Pae, C., Han, K., et al. (2025) · BMC Psychiatry · doi:10.1186/s12888-024-06381-z · Cited by 4
“The use of antidepressants (e.g., amitriptyline bupro-pion) [46], anti-psychotics (e.g., olanzapine clozapine) [47], anti-obesity drugs (e.g., Phentermine, Phentermine-topiramate), which have the potential to affect both body weight and risk of suicide, may have influenced the results of our study.”
Falaiye, T. A., Okobi, O. E., Oramu, C. I., & Jegede, A. O. (2025) · Cureus · doi:10.7759/cureus.78251 · Cited by 3
“Thus, tackling existing weight biases among clinicians and other healthcare professionals is likely to enhance patient care outcomes through the creation of a space in which individuals develop a sense of being understood and respected [90].”
The BMIgap tool to quantify transdiagnostic brain signatures of current and future weight
Khuntia, A. T., Popovic, D., Sarisik, E., Buciuman, M.-O., Pedersen, M. L., Westlye, L. T., Andreassen, O. A., Meyer‐Lindenberg, A., Kambeitz, J. P., Salokangas, R. K. R., et al. (2025) · Nature Mental Health · doi:10.1038/s44220-025-00522-3 · Cited by 2
“Antidepressants affect metabolic risk by increasing appetite and suppressing satiety, primarily through histaminergic and serotonin receptor antagonism 11,12 .”
Metabolic and toxicological considerations for obsessive–compulsive disorder drug therapy
Sayyah, M., Majzoob, S., & Sayyah, M. (2013) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2013.783011 · Cited by 2
“Paroxetine is associated with a greater risk of weight gain among SSRIs [85].”
BackgroundDuloxetine in panic disorder with somatic gastric pain
Preve, M., Nisita, C., Bellini, M., et al. (2013) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s35922 · Cited by 2
Riesenberg, R. A., Rosenthal, J., Moldauer, L., & Peterson, C. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2604-x · Cited by 2
“Weight gain is also a common adverse side effect (Serretti and Mandelli 2010) which may lead to obesity, increased risk of type 2 diabetes,(Kivimäki et al.”
BackgroundDepression, Antidepressant Use and Weight Gain*
Wehby, G. L., & Yang, M. (2012) · Cited by 2
Weighty matters: the association between mental health, pregnancy, and obesity.
Taylor, V. H. (2012) · PubMed · Cited by 2
Robinson, D. J., Luthra, M., & Vallis, M. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.07.025 · Cited by 3
Troubles affectifs et troubles des conduites alimentaires
Fakra, É., Belzeaux-R, R., Azorin, J., & Adida, M. (2014) · L Encéphale · doi:10.1016/s0013-7006(14)70131-9 · Cited by 2
The association between antidepressant use and hemoglobin A1C in older adults
Kammer, J., Hosler, A. S., Leckman‐Westin, E., & DiRienzo, A. G. (2016) · Geriatric Nursing · doi:10.1016/j.gerinurse.2016.09.002 · Cited by 2
Trazodone: The Forgotten Antidepressant
Raatjes, B., & Dantz, B. (2011) · Psychiatric Annals · doi:10.3928/00485713-20110224-04 · Cited by 2
Blampied, M., Bell, C., Gilbert, C., Boden, J. M., Nicholls, R. J., & Rucklidge, J. J. (2018) · Medicines · doi:10.3390/medicines5020056 · Cited by 2
The Antidepressants and the Metabolic Syndrome
Kolcsár, M., Gáll, Z., Bába, L.-I., & Zoltán, K. I. (2018) · Orvostudományi Értesítö · doi:10.2478/orvtudert-2018-0009 · Cited by 2
“Kiindulhatunk a depresszió és az MS kölcsönösségéből: a depresszió gyakran okoz MS-t és viszont; ugyanakkor a két kórkép egymást súlyosbítja.”
InfluentialLong-Term Implications of Developmental Programming and Obesity
Heindel, J. J. (2019) · Current topics in environmental health and preventive medicine · doi:10.1007/978-981-15-0520-1_9 · Cited by 3
Maternal Gestational Weight Gain in Relation to Antidepressant Continuation in Pregnancy
Wartko, P. D., Weiss, N. S., Enquobahrie, D. A., Chan, K. C. G., Stephenson‐Famy, A., Mueller, B. A., & Dublin, S. (2020) · American Journal of Perinatology · doi:10.1055/s-0040-1713652 · Cited by 2
Lian, W., Livneh, H., Huang, H.-J., Lu, M., Guo, H., & Tsai, T. (2021) · Frontiers in Public Health · doi:10.3389/fpubh.2021.650452 · Cited by 3
“Some of these medications, however, may induce adverse side effects such as weight gain and decreased glycemic control (4, 8, 9).”
BackgroundKey Concepts in Screening for Depression in People with Diabetes
Holt, R. I. G., & Feltz-Cornelis, C. M. V. D. (2012) · Springer eBooks · doi:10.1007/978-0-85729-751-8_3 · Cited by 2
Ranney, R. M., Maguen, S., Woods, A., Seal, K. H., Neylan, T. C., Bernardy, N. C., Wiechers, I. R., Ryder, A. L., & Cohen, B. E. (2022) · Journal of Evaluation in Clinical Practice · doi:10.1111/jep.13726 · Cited by 3
Alteração de peso em pacientes em tratamento com antidepressivos: Revisão narrativa
Solis, E. A., Leonello, C. D. M. R., & Mendes-Gomes, J. (2022) · Research Society and Development · doi:10.33448/rsd-v11i12.34904 · Cited by 2
“Por exemplo, a fluoxetina, geralmente, causa perda de peso no início do tratamento (Serretti & Mandelli, 2010), mas após os primeiros seis meses de tratamento, o peso gradualmente se eleva, a despeito da continuação de uso da medicação (Behar, 2002 como citado em de Oliveira et al., 2012; D'arga et…”
BackgroundInfluentialA Review on Drug Induced Obesity and Rodent Experimental Models of Obesity in Animals
Vangoori, Y., Suresh, B. S., Midde, M. L., Anusha, D., & Uppala, P. K. (2022) · MAEDICA – a Journal of Clinical Medicine · doi:10.26574/maedica.2022.17.3.706 · Cited by 2
Azar, K. M. J., Sudat, S. E. K., Huang, Q., Pressman, A. R., Szwerinski, N., Nasrallah, C., Venditti, E. M., & Romanelli, R. J. (2023) · Obesity Science & Practice · doi:10.1002/osp4.696 · Cited by 2
“26 Depression and anxiety have been associated with both weight loss 27–29 and weight gain 27,28,30,31 , representing a paradox that has been much studied.”
BackgroundTreatment for Depression and the Risk of Weight Gain
Heiskanen, T. H. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14com09738 · Cited by 2
Psychopharmaka-induzierte unerwünschte Wirkungen in der Ernährungstherapie
Schlumm, K., Sina, C., Schröder, T., & Smollich, M. (2019) · Aktuelle Ernährungsmedizin · doi:10.1055/a-0942-9167 · Cited by 2
“So korreliert die Gewichtszunahme nach Therapiebeginn sowohl bei Antipsychotika als auch bei Antidepressiva mit der H1-Rezeptoraffinität des jeweiligen Wirkstoffs: je höher die H1-antagonistische Partialwirkung, desto stärker die Gewichtszunahme [27].”
BackgroundSterke, S. (2011) · RePub (Erasmus University Rotterdam) · Cited by 2
Wong, B. C., Chau, C. K., Ao, F., Mo, C., Wong, S., Wong, Y. H., & So, H. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/140590 · Cited by 2
St‐Amour, S., Hains-Monfette, G., Dancause, K. N., et al. (2020) · doi:10.31236/osf.io/7qnmf · Cited by 2
Liu, X., Tian, X. S., Wang, L., & Zhang, X. (2024) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-024-01766-3 · Cited by 2
“A meta-analysis showed that one potential factor contributing to obesity in MDD was the use of antipsychotic drugs, but this still remains controversial [13, 14].”
Shamim, M. A., Shukla, R. K. G., Swami, M. K., Srivastav, S., Pradhan, A., Yadav, S. S., Anil, A., Saravanan, A., Varthya, S. B., Singh, S., et al. (2024) · BMJ Open · doi:10.1136/bmjopen-2023-077975 · Cited by 3
“38 This corroborates using bupropion with naltrexone for weight loss in individuals with weight-related multimorbidities like T2D.”
MethodTransforming the diabetes outcomes for people with mental illness
Holt, R. I. G. (2024) · Practical Diabetes · doi:10.1002/pdi.2516 · Cited by 1
Lee, H. J., Kim, N. Y., Kim, D. S., Kim, Y., Kim, J., Han, D. H., & Kim, S. M. (2025) · PLoS ONE · doi:10.1371/journal.pone.0324000 · Cited by 1
“In a meta-analysis of weight gain as the side effect of antidepressants, mirtazapine showed the highest risk of weight gain, excluding tricyclic antidepressants that are no longer used as first-line therapy in the treatment of depression [10,12,13].”
Yu, Q., Li, H., Cui, X., Zhou, L., Xie, Z., Wang, S., Deng, D., Zhao, J., Sun, P., Shi, Y., et al. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1508037 · Cited by 1
“Additionally, similar to other antidepressants (Serretti and Mandelli, 2010), SNS demonstrated a signi fi cant reversal of reduction in appetite and body weight in depressed rats.”
Erbakan, M., & Torun, C. (2025) · Mediterranean Journal of Nutrition and Metabolism · doi:10.1177/1973798x251349603 · Cited by 1
“35 Prospective studies are needed to further investigate the relationship between psychiatric support, weight changes, and metabolic control to con fi rm and expand upon these fi ndings.”
Tuccinardi, D., Conte, C., Λαμπροπούλου, Α., Galasso, M., Bertoccini, L., Shang, M., & Artime, E. (2025) · Journal of Endocrinological Investigation · doi:10.1007/s40618-025-02693-3 · Cited by 1
“Some of these medications are associated with changes in body weight, which can further complicate the management of obesity [33].”
Beckett, C. W., & Lawson, R. P. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.120731 · Cited by 2
Cheng, H., Jing, Y., Xu, C.-J., Chen, M., Su, H., Yang, X.-P., & Zhang, L.-Y. (2026) · Drug Design, Development and Therapy · doi:10.2147/dddt.s567851 · Cited by 2
“However, several limitations of traditional antidepressants such as weight gain, 10 increased cardiovascular risk, 11 and other metabolic adverse effects, 12 combined with their inherently slow onset of action (typically 2–4 weeks) and suboptimal treatment response rates (with only approximately…”
InfluentialNadubinszky, G., Vonyik, G., & Székács, B. (2026) · Orvosi Hetilap · doi:10.1556/650.2026.33499 · Cited by 1
Li, S.-C., Xu, L., Liang, H., Wang, Y., Shen, Y.-P., & Liu, X. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1842720
“Antidepressant use may have influenced both TyG-related metabolic profiles and cardiovascular outcomes through effects on body weight, adiposity, glucose metabolism, lipid profiles, blood pressure, and other cardiometabolic risk factors (15, 16).”
Antidepressant-Induced Sexual Dysfunction in Adults
Zini, J., & Turecki, G. (2026) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000002210 · Cited by 2
Individualisierte Behandlungsstrategien bei depressiven Störungen
Fehler, S., & Landgrebe, M. (2015) · Zeitschrift für Psychiatrie Psychologie und Psychotherapie · doi:10.1024/1661-4747/a000245 · Cited by 1
Cubells, J. F. (2011) · Current Psychiatry Reports · doi:10.1007/s11920-011-0179-1 · Cited by 1
“The psychopharmacology of obesity is an important topic from the point of view of pharmacologic treatments aimed at influencing feeding behavior [1], as well as the myriad antipsychotic and antidepressant medications associated with changes in body weight [2, 3].”
Psychotropic Drugs Induced Weight Gain
Wongpakaran, R., & Boonlue, T. (2015) · Srinagarind Medical Journal (SMJ) - ศรีนครินทร์เวชสาร · Cited by 1
Metabolische Nebenwirkungen von Psychopharmaka
Zeiss, R., Connemann, B. J., & Gahr, M. (2017) · DNP - Der Neurologe und Psychiater · doi:10.1007/s15202-017-1494-0 · Cited by 1
“Auch zahlreiche Antidepressiva, die eine hohe Aμnität für histaminerge Rezeptoren aufweisen (wie Trizyklika und das noradrenerge und spezi sch serotonerge Antidepressivum [NaSSA] Mirtazapin), sind mit einer Gewichtszunahme assoziiert [68].”
BackgroundWeight Gain on Psychotropic Drugs: Has the Obesity Community been Paying Attention?
Wurtman, J. J. (2015) · Journal of Obesity & Weight loss Therapy · doi:10.4172/2165-7904.1000271 · Cited by 1
“Similar amounts of weight have been gained during treatment with paroxetine [4] but this particular drug has the potential to cause even greater weight gain.”
BackgroundInfluentialPsychopharmakotherapie und metabolische Nebenwirkungen
Connemann, B. J., Gahr, M., & Zeiss, R. (2017) · Nervenheilkunde · doi:10.1055/s-0038-1627514 · Cited by 1
“, die 116 Studien einschloss und in der Mirtazapin und Paroxetin, jedoch auch Amitriptylin, mit dem größten Risiko für eine Gewichtszunahme assoziiert waren (55).”
BackgroundDiabetogenic Effects Associated with Psychiatric Treatment
Mamakou, V., Eleftheriadou, I., Tentolouris, A., Sabanis, N., Drylli, A., & Tentolouris, N. (2018) · Current Pharmacology Reports · doi:10.1007/s40495-018-0126-5 · Cited by 1
Jaffe, R. J., Juneja, N. S., Juneja, N. S., et al. (2018) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2018.29152.bjc · Cited by 1
“Interestingly, there are currently very limited data on fluvoxamine with regard to changes in weight (Serretti and Mandelli 2010).”
Selective Serotonin Reuptake Inhibitors (SSRIs) and Weight Gain
Igel, L. I. (2018) · Obesity Management · doi:10.1007/978-3-030-01039-3_7 · Cited by 1
Gewichtsänderung als unerwünschte Arzneimittelwirkung
Engeli, S., & May, M. (2020) · Adipositas - Ursachen Folgeerkrankungen Therapie · doi:10.1055/a-1207-8003 · Cited by 1
“So weisen Autoren einer älteren Meta-Analyse zum Einsatz von Antidepressiva innerhalb der Indikation Depression darauf hin, dass Fluoxetin zwar bei kurz dauernder Therapie akut zu einer gewissen Gewichtabnahme führt, bei länger dauernder Therapie aber eher gewichtsneutral sei, anders als das immer „wirksame“ Bupropion…”
BackgroundInfluentialDiabetes, Depression, and Cognitive Disorders
Holt, R. I. G. (2018) · Endocrinology · doi:10.1007/978-3-319-44433-8_24 · Cited by 1
Laux, G. (2017) · Springer eBooks · doi:10.1007/978-3-662-49295-6_67 · Cited by 2
Laux, G. (2017) · Springer eBooks · doi:10.1007/978-3-662-53697-1_11 · Cited by 1
Zheng, Y., Meyerowitz‐Katz, G., Bramwell, S., Jayaballa, R., Assur, Y., Vasani, D., Ganapathy, R., MABERLY, G. F., & Brakoulias, V. (2022) · The Journal of Nervous and Mental Disease · doi:10.1097/nmd.0000000000001590 · Cited by 1
Antidepressiva – State of the Art
Lange‐Asschenfeldt, C. (2023) · Zeitschrift für Gerontologie und Geriatrie · doi:10.1007/s00391-023-02169-0 · Cited by 1
“[18] fanden jedoch in einer Metaanalyse, dass sich auch diese Substanzklassen in der langfristigen Erhaltungstherapie (>4 Monate) gewichtsneutral oder gewichtssteigernd auswirken können.”
BackgroundSeifert, J., Bleich, S., & Seifert, R. (2023) · Springer eBooks · doi:10.1007/978-3-662-68371-2_22 · Cited by 1
Wal, P., Kumar, P., Bhardwaj, H., Sharma, K., Tripathi, A. K., Gupta, A., Wal, A., & Sharma, M. C. (2024) · Current Diabetes Reviews · doi:10.2174/0115733998288090240509105717 · Cited by 1
Weight Management and Metabolism in Postmenopausal Women: A Review
Pal, D., & Sharma, S. (2024) · International Journal of Innovative Science and Research Technology (IJISRT) · doi:10.38124/ijisrt/ijisrt24jul216 · Cited by 1
Metabolische unerwünschte Arzneimittelwirkungen von Psychopharmaka
Gahr, M. (2024) · Fortschritte der Neurologie · Psychiatrie · doi:10.1055/a-2405-5087 · Cited by 1
“Esketamin, Desvenlafaxin, Moclobemid sowie Agomelatin sind mit einem geringen Risiko für Gewichtszunahme assoziiert [25, 26].”
Yoshida, S., Aizawa, E., Ishihara, N., Hattori, K., Segawa, K., & Kunugi, H. (2025) · Nutrients · doi:10.3390/nu17040613 · Cited by 1
“It is known that antide-pressants such as mirtazapine, amitriptyline, and paroxetine have significant weight gain effects in maintenance therapy (reviewed in [51]), which may confer the risk of developing DM or a prediabetic state.”
Schuurman, L. J. M., Sobczak, S., Schulkens, J. E. M., Balter, B. P. F., & van Alphen, S. P. J. (2025) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.70009 · Cited by 1
Insulin resistance in major depressive disorder and the effects of psychotropic medications
Mason, J. S., Kenna, H. A., & Rasgon, N. (2012) · Clinical Practice · doi:10.2217/cpr.12.46 · Cited by 1
Bupropion confirmed not to cause weight gain in a real-world clinical population
Patten, S. B. (2015) · Evidence-Based Mental Health · doi:10.1136/eb-2014-101978 · Cited by 1
“The literature is consistent in identifying bupropion as an antidepressant that is less likely to cause weight gain than other antidepressants.(2) However, there appears to be considerable heterogeneity in the effects of these medications.”
BackgroundInfluentialFive Decades of Hormone Therapy Research: The Long, the Short, and the Inconclusive
Sayegh, R. A., & Awwad, J. T. (2017) · Springer eBooks · doi:10.1007/978-3-319-42451-4_2 · Cited by 1
Diabetes, Depression, and Cognitive Disorders
Holt, R. I. G. (2018) · Endocrinology · doi:10.1007/978-3-319-27316-7_24-1 · Cited by 1
Az antidepresszívumok és a cukorbetegség közti kapcsolat
Hargittay, C., Gonda, X., Márkus, B., Vörös, K., Tabák, Á. G., Kalabay, L., Rihmer, Z., & Torzsa, P. (2020) · Lege Artis Medicinae · doi:10.33616/lam.30.016 · Cited by 1
“Az SSRI-szerek a többi antidepresszívum-készítményhez képest kevésbé okoznak súlygyarapodást, kivéve a paroxetin (32).”
Weight loss: Lifestyle interventions and pharmacotherapy
Poku, C. A., Tahsin, B., & Fogelfeld, L. A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-815290-4.00016-6 · Cited by 2
Silva, D. A., Coutinho, E. S. F., de Figueiredo, R. C., Molina, M. D. C. B., Mill, J. G., de Faria, C. P., Nunes, M. A., Moreno, A. B., Giatti, L., Barreto, S. M., et al. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.12.091 · Cited by 1
唐, 一. (2020) · Advances in Clinical Medicine · doi:10.12677/acm.2020.1012461 · Cited by 1
Diabetes, Depression, and Cognitive Disorders
Holt, R. I. G. (2020) · Endocrinology · doi:10.1007/978-3-030-36694-0_24 · Cited by 1
Endocrine Disruptor Compounds: Human Health and Diseases
Kurjogi, M. M., Vanti, G. L., & Kaulgud, R. S. (2022) · Springer eBooks · doi:10.1007/978-981-16-9001-3_25 · Cited by 1
Diagnostik und Ätiologie der Adipositas
Wirth, A. G. (2022) · Springer eBooks · doi:10.1007/978-3-662-63544-5_55 · Cited by 1
TRICYCLIC AND SSRI USAGE INFLUENCES THE ASSOCIATION BETWEEN BMI AND HEALTH RISK FACTORS
Carlton, K. J. (2014) · YorkSpace (York University) · Cited by 1
The Tricyclics: More than Just Antidepressants
Plattner, A., & Dantz, B. (2011) · Psychiatric Annals · doi:10.3928/00485713-20110224-05 · Cited by 1
Noradrenergic and specific serotonergic antidepressants
Heck, E., & MacQUEEN, G. M. (2012) · doi:10.2217/ebo.11.227 · Cited by 3
Pharmacological Treatment of Generalized Anxiety Disorder (GAD)
Baldwin, D. S. (2020) · Wiley eBooks · doi:10.1002/9781119189909.ch14 · Cited by 1
Metadata
- Authors
- Serretti, A., & Mandelli, L.
- Affiliations
- University of Bologna (IT)
- Corresponding author
- Serretti, Alessandro
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2010-10-15
- Volume
- 71
- Issue
- 10
- Pages
- 1259-1272
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2030270520
- Cited by
- 621
- References
- 0
- Citations by year
- 2026: 40 · 2025: 44 · 2024: 46 · 2023: 41 · 2022: 42 · 2021: 41 · 2020: 33 · 2019: 36 · 2018: 37 · 2017: 36 · 2016: 31 · 2015: 47 · 2014: 40 · 2013: 49 · 2012: 41
- FWCI
- 25.11
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Clinical Psychology › Eating Disorders and Behaviors
- Keywords
- antidepressants, weight gain, body weight, psychotropic drugs, obesity, amitriptyline, mirtazapine, paroxetine, fluoxetine, bupropion, tricyclic antidepressants, selective serotonin reuptake inhibitors, adverse drug reactions, treatment discontinuation
- MeSH terms
- Antidepressive Agents, Body Weight, Clinical Trials as Topic, Humans, Time Factors, Weight Gain, Weight Loss
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
